Deborah H. McCollister

Learn More
Pulmonary arterial hypertension (PAH) is a rare and debilitating disease characterised by progressive increases in pulmonary arterial pressure and pulmonary vascular resistance, leading to right ventricular failure and death (1–4). As there is no cure, the primary goal of disease management is to alleviate symptoms and prolong survival. Although treatment(More)
BACKGROUND In patients with left-heart disease, depressive symptoms have a significant impact on functional status and quality of life. The prevalence of depressive symptoms, and their impact on patients with pulmonary arterial hypertension (PAH) is understudied. OBJECTIVE The authors investigated the prevalence of depressive symptoms in PAH and their(More)
BACKGROUND Selective serotonin reuptake inhibitors (SSRIs) have been suggested to offer therapeutic benefit in patients with pulmonary arterial hypertension (PAH). We conducted two analyses to explore the association between SSRI use and PAH outcomes using the Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL Registry). METHODS(More)
BACKGROUND Regulators and clinical experts increasingly recognize the importance of incorporating patient-reported outcomes (PROs) in clinical studies of therapies for pulmonary arterial hypertension (PAH). No PAH-specific instruments have been developed to date in accordance with the 2009 FDA guidance for the development of PROs as endpoints in clinical(More)
David B. Badesch, MD Professor of Medicine Clinical Director Pulmonary Hypertension Center University of Colorado Denver Aurora, CO The recent identification of depression as an important comorbidity in pulmonary arterial hypertension (PAH)1,2 is leading to a broad array of efforts to further refine our understanding of this disorder, enhance patient and(More)
  • 1